Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
48 patients around the world
Available in United States, Brazil, Peru
A5394 is a phase II, double-blinded, placebo-controlled trial. Forty-eight study
participants will be randomized 3:1 to receive SLGN or its placebo (36 active and 12
placebo), and randomization will be stratified by HBeAg status. One-half of the study
participants will be HBeAg positive (n=24) at screening, and the other half will be HBeAg
negative (n=24). All participants will remain on their non-study-provided antiviral
therapy throughout the study.
National Institute of Allergy and Infectious Diseases (NIAID)
3Research sites
48Patients around the world
This study is for people with
Hiv
Hepatitis
Hepatitis b
Requirements for the patient
To 70 Years
All Gender
Medical requirements
Sites
Hospital Nossa Senhora da Conceição
Av. Francisco Trein, 596 – 2º andar - Bairro: Cristo Redentor - CEP 91350-200 - Porto Alegre
Instituto Nacional de Infectologia Evandro Chagas
Av. Brasil, 4365 - Manguinhos, Rio de Janeiro - RJ, 21040-360
Asociación Civil Impacta Salud y Educación - Barranco Clinical Research Site
Av. Almirante Miguel Grau 1010, Barranco, Lima 04
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)